Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

667
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
667
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

1.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.6K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

164
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
164
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

552
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
552
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

266
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
266

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

Journal of the American Heart Association·2026
Same author

New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.

Circulation research·2026
Same author

Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry.

European heart journal·2026
Same author

Homozygous familial hypercholesterolemia: Will new LDL-C-lowering drugs replace lipoprotein apheresis?

European journal of preventive cardiology·2026
Same author

The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.

Cardiovascular diabetology·2026
Same author

CETP Renaissance with Obicetrapib.

Current atherosclerosis reports·2026

Related Experiment Video

Updated: Jul 8, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.0K

How to Handle Elevated Triglycerides: Life after PROMINENT.

Angela Pirillo1, Alberico L Catapano2,3

  • 1Center for the Study of Atherosclerosis, E. Bassini Hospital, Cinisello Balsamo, Milan, Italy.

Current Atherosclerosis Reports
|December 20, 2023
PubMed
Summary

Hypertriglyceridaemia (HTG) management is complex, as lowering triglycerides alone may not reduce cardiovascular risk. New drugs targeting apolipoprotein C-III or angiopoietin-like-3 may offer future benefits.

Keywords:
Apolipoprotein BAtherogenic lipoproteinsHypertriglyceridaemiaTG-rich lipoproteinsTriglycerides

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Related Experiment Videos

Last Updated: Jul 8, 2025

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

4.0K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Pharmacology

Background:

  • Hypertriglyceridaemia (HTG) is common, with elevated triglycerides (TG) linked to cardiovascular risk.
  • Severe HTG poses a risk for acute pancreatitis.
  • TG-lowering drug trials show conflicting results regarding cardiovascular benefits.

Purpose of the Study:

  • To review the current understanding of hypertriglyceridaemia and its treatment.
  • To evaluate the effectiveness of various triglyceride-lowering drugs in reducing cardiovascular risk.
  • To explore emerging therapeutic targets for managing HTG.

Main Methods:

  • Review of randomized clinical trials and recent findings on triglyceride-lowering therapies.
  • Analysis of the role of different triglyceride-rich lipoproteins (TRLs) in cardiovascular risk.
  • Examination of the impact of specific drugs like fibrates and omega-3 fatty acids.

Main Results:

  • Triglyceride reduction alone is insufficient for cardiovascular risk reduction; lowering atherogenic lipoproteins (measured by apolipoprotein B) is crucial.
  • Fibrates benefit only specific patient subgroups.
  • Icosapent ethyl shows promise, potentially beyond lipid effects; new drugs targeting apoC-III or angiopoietin-like-3 are under development.

Conclusions:

  • Effective HTG management requires more than just lowering TG levels; reducing atherogenic lipoproteins is key.
  • Future therapies targeting apoC-III or angiopoietin-like-3 may prove more effective in reducing cardiovascular risk.
  • Outcome studies on new drugs will determine if lowering apoB is critical for clinical benefit.